Three receptors, three signalling pathways, and an entire generation of incretin-class research peptides built around engaging them. Here is the comparative pharmacology.
GLP-1, GIP and glucagon receptors are all class B (secretin-like) G-protein-coupled receptors, and all three are activated by structurally related peptide hormones derived from a common evolutionary lineage. Understanding how each receptor signals — and where their downstream pathways converge or diverge — is the foundation for interpreting research on mono-, dual- and triple-agonist peptides.
Receptor biology overview
| Receptor | Native ligand | Primary expression | Canonical signalling |
|---|---|---|---|
| GLP-1R | GLP-1 (from proglucagon in L-cells) | Pancreatic β-cells, CNS, gastric, cardiac | Gs/cAMP, glucose-dependent insulin secretion |
| GIPR | GIP (from K-cells) | Pancreatic islets, adipocytes, CNS, bone | Gs/cAMP, adipocyte lipid handling |
| GCGR | Glucagon (from pancreatic α-cells) | Hepatocytes, adipocytes, kidney | Gs/cAMP, hepatic glucose output, lipolysis |
Why GLP-1 became the first major research target
GLP-1's role in glucose-dependent insulin secretion made it an early and obvious research target: activation only potentiates insulin release when blood glucose is elevated, which is mechanistically distinct from insulin itself. Native GLP-1 is degraded within roughly two minutes by the enzyme dipeptidyl peptidase-4 (DPP-4), which is why essentially the entire GLP-1 agonist research literature exists to solve a single stability problem through backbone modification and fatty-acid conjugation.
Aib8 substitution and fatty-acid conjugation
Two engineering strategies dominate the published literature: substituting the DPP-4 cleavage site with α-aminoisobutyric acid (Aib) at position 8 to block enzymatic degradation, and conjugating a fatty-diacid moiety through a linker to enable reversible albumin binding, which slows renal clearance. Semaglutide and its successors combine both strategies.
How GIP co-agonism changes the pharmacological picture
GIP receptor agonism engages adipocyte-expressed GIPR alongside pancreatic and CNS expression. Research literature on dual GIP/GLP-1 agonists such as tirzepatide describes additive or synergistic signalling at metabolic endpoints relative to GLP-1 agonism alone, and GIPR's expression pattern in adipose tissue is a focus of ongoing structure-function research into lipid handling pathways.
Why glucagon receptor agonism is the more complex addition
Glucagon receptor activation is canonically associated with raising hepatic glucose output through glycogenolysis and gluconeogenesis — an effect that runs counter to the glucose-lowering signalling of GLP-1R and GIPR. Triple-agonist molecules such as retatrutide are engineered as partial rather than full glucagon receptor agonists specifically to balance this tension, and calibrating that balance is one of the more active areas of current SAR (structure-activity relationship) publication.
Comparative agonist classes
- Mono-agonists (e.g. semaglutide): engage GLP-1R only.
- Dual agonists (e.g. tirzepatide): engage GIPR and GLP-1R.
- Triple agonists (e.g. retatrutide): engage GIPR, GLP-1R and partial GCGR.
- Amylin-pathway analogs (e.g. cagrilintide): engage the amylin/calcitonin receptor complex, a mechanistically separate but often co-studied pathway.
Reading receptor-binding assay data
Published binding-affinity data for these peptides is typically reported as EC50 values from cAMP-accumulation assays in receptor-transfected cell lines, expressed relative to the native hormone. A lower EC50 indicates higher potency at a given receptor. When comparing molecules across published studies, check that the assay system and cell line are consistent, since EC50 values are not always directly comparable across different experimental platforms.
Frequently asked questions
What type of receptor are GLP-1R, GIPR and GCGR?
All three are class B (secretin-like) G-protein-coupled receptors that primarily signal through the Gs/cAMP pathway.
Why is native GLP-1 unsuitable as a research peptide without modification?
Native GLP-1 is degraded by DPP-4 within approximately two minutes in circulation, so essentially all GLP-1 agonist research peptides incorporate backbone or conjugation modifications to extend stability.
Why is glucagon receptor agonism engineered as partial rather than full in triple agonists?
Full glucagon receptor agonism raises hepatic glucose output, so partial agonism is used to balance that effect against the glucose-lowering signalling from GLP-1R and GIPR.
How is receptor potency typically reported in published literature?
Most published data reports EC50 values from cAMP-accumulation assays in receptor-transfected cell lines, expressed relative to the native hormone.
